Patent intelligence · WO
WO 2025233501
CONJUGUÉS COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I
CONJUGUÉS COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I
Patent details — WO 2025233501
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Nov 13, 2025
- Expiration
- Nov 8, 2045
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61K 47/ 68 A I, A61K/4768037, A61K/476851, A61K/476855
Quick answer
WO 2025233501 (CONJUGUÉS COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Nov 13, 2025. Expires Nov 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 68 A I, A61K/4768037, A61K/476851, A61K/476855, A61K/476883, A61K/476889
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2025233501?
WO 2025233501 (CONJUGUÉS COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Nov 13, 2025. Expires Nov 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025233501?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does WO 2025233501 expire?
Our index shows an expiration date of Nov 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.